

1 **Full title**

2 Systematic Living Evidence for Clinical Trials (SyLECT): a data-driven framework for drug
3 selection in clinical trials in motor neuron disease.

4 **Short title**

5 Data-driven drug selection for clinical trials in motor neuron disease

6 **Authors and affiliations**

7 Charis Wong¹⁻⁴, Alessandra Cardinali^{1,3,5}, Jing Liao¹, Bhuvaneish T. Selvaraj^{1-3,5}, Paul
8 Baxter^{5,8}, Roderick N. Carter^{1,5}, James Longden^{1,3,5}, Rebecca E. Graham^{3,9}, Rachel S.
9 Dakin¹⁻³, Suvankar Pal¹⁻³, Jeremy Chataway^{4,6,7}, Robert Swingler³, Giles E. Hardingham^{3,5,8},
10 Neil Carragher⁹, Siddharthan Chandran^{1-3,5}, Malcolm Macleod^{1*} on behalf of the ReLiSyR-
11 MND consortium[^]

12
13 ¹Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK, ²Anne
14 Rowling Regenerative Neurology Clinic, University of Edinburgh, UK, ³Euan MacDonald
15 Centre for Motor Neuron Disease Research, University of Edinburgh, Edinburgh, UK,
16 ⁴Medical Research Council Clinical Trials Unit at UCL, Institute of Clinical Trials and
17 Methodology, University College London, London, UK, ⁵UK Dementia Research Institute at
18 University of Edinburgh, University of Edinburgh, Edinburgh bioQuarter, Chancellor's
19 Building, 49 Little France Crescent, Edinburgh, UK, ⁶Queen Square Multiple Sclerosis
20 Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology,
21 Faculty of Brain Sciences, University College London, London, UK, ⁷National Institute for
22 Health Research, University College London Hospitals, Biomedical Research Centre,

23 London, UK, ⁸Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh,
24 UK, ⁹MRC Institute of Genetics & Cancer, The University of Edinburgh, Edinburgh, UK.

25

26 **ORCID iD**

27 Charis Wong 0000-0002-8488-037X

28 Jing Liao 0000-0002-9591-8070

29 Bhuvaneish T. Selvaraj 0000-0001-7299-0910

30 Paul Baxter 0000-0003-2142-1085

31 Rebecca E. Graham 0000-0002-0590-4135

32 Rachel S. Dakin 0000-0002-3697-8516

33 Suvankar Pal 0000-0003-4276-639X

34 Jeremy Chataway 0000-0001-7286-6901

35 Giles E. Hardingham 0000-0002-7629-5314

36 Neil Carragher 0000-0001-5541-9747

37 Siddharthan Chandran 0000-0001-6827-1593

38 Malcolm R. Macleod 0000-0001-9187-9839

39

40 ***Corresponding author:**

41 Malcolm Macleod

42 Centre for Clinical Brain Sciences, Chancellor's Building, 49 Little France Crescent,

43 Edinburgh EH16 4SB.

44 Malcolm.macleod@ed.ac.uk

45

46 ^Membership of the ReLiSyR-MND consortium is provided in the Acknowledgements

47 **Abstract**

48 Despite many promising preclinical studies and decades of clinical trials, there remains a
49 paucity of effective disease-modifying drugs in motor neuron disease. We aimed to develop a
50 systematic and structured data-driven framework to identify, evaluate and prioritise candidate
51 drugs for clinical trials, specifically for the Motor Neuron Disease-Systematic Multi-Arm
52 Adaptive Randomised Trial (MND-SMART; NCT040302870). We developed the Systematic
53 Living Evidence for Clinical Trials (SyLECT) platform as a modular framework integrating
54 emerging data from different domains to inform prioritisation of candidate drugs. Current
55 domains incorporated include published clinical, animal *in vivo*, and *in vitro* literature; in
56 house *in vitro* high throughput drug screening; pathway and network analysis; and
57 pharmacological, feasibility and clinical trial data from drug, chemical, and clinical trial
58 databases. In this approach, we first identify a list of candidate drugs from these domains then
59 select drugs for further consideration based on drug properties, feasibility, and expert
60 opinion. For prioritised drugs we then generate, evaluate, and synthesise further evidence
61 from across data domains. Using automated workflows and interactive web applications, we
62 produce snapshot “living evidence summaries” to inform expert panel decisions on
63 prioritisation of candidate drugs for MND-SMART. The third drug selected for MND-
64 SMART and the first using this framework is amantadine. We demonstrated the feasibility of
65 a systematic data-driven framework to inform prioritisation of candidate drugs for clinical
66 trials in motor neuron disease, with potential for wider application across diseases where
67 there is unmet clinical need.

68

69 **Keywords:** Motor neuron disease, neurodegenerative diseases, evidence synthesis, clinical
70 trials, drug repurposing

71 **Key messages**

72

73 What is already known on this topic:

- 74 - Despite extensive preclinical research and clinical trials for disease-modifying
75 treatments in motor neuron disease, translational success remains elusive.
76 - Advances in research across biological domains presents a wealth of data to guide
77 prioritisation of candidate drugs for clinical trials.

78

79 What this study adds

- 80 - This study demonstrates the feasibility of using a systematic, modular, data-driven
81 framework to inform prioritisation of candidate drugs for an adaptive platform trial in
82 motor neuron disease.

83

84 How this study might affect research, practice or policy:

- 85 - The framework could be applied to inform prioritisation of drugs for clinical trials in
86 other diseases, especially adaptive platform trials in neurodegenerative diseases.

87

88 **Introduction**

89 Motor neuron disease (MND, alternatively amyotrophic lateral sclerosis (ALS)), is a
90 progressive, disabling and ultimately fatal neurodegenerative disease. In many countries
91 including the United Kingdom (UK), riluzole remains the only approved disease-modifying
92 drug, with an average survival benefit of 2-3 months.(1) Edaravone, masitinib and AMX0035
93 have emerged as promising candidates with positive trials in highly stratified cohorts.(2-5)
94 However, evidence of generalisable survival benefit remains limited, and none of these drugs
95 have been granted marketing authorisation for MND/ALS in Europe. The paucity of effective
96 disease-modifying treatments despite numerous clinical trials and promising preclinical
97 studies reflects the challenges in selecting and evaluating drugs for clinical trials,
98 compounded by limitations in our understanding of MND disease biology.(6) However,
99 recent adaptive platform trials such as the Motor Neuron Disease – Systematic Multi-Arm
100 Adaptive Randomised Trial (MND-SMART; EudraCT Number: 2019-000099-41;
101 ClinicalTrials.gov registration number: NCT04302870),(7) HEALEY ALS Platform Trial
102 (ClinicalTrials.gov registration number: NCT04297683),(8) and the TRICALS ‘MAGNET’
103 platform trial (EudraCT number: 2020-000579-19)(9) provide efficient infrastructures to
104 evaluate pipelines of candidate drugs, offering significant reduction in overall sample size,
105 cost and time compared to consecutive two-arm trials with traditional fixed designs.(6, 10)
106
107 There is, therefore, an urgent need to optimise drug selection and prioritisation for clinical
108 trials in MND. Historically, these decisions have been largely informed by mouse studies,
109 with inherent limitations in modelling human disease. Most of these studies use superoxide
110 dismutase (SOD1) mouse models which do not recapitulate the TAR DNA binding protein 43
111 (TDP-43) proteinopathy seen in 97% of people with sporadic MND.(11) A reported lack of

112 reproducibility and rigour of many of these studies likely further contributes to translational
113 failure.(12)

114

115 These limitations might be mitigated by taking a more comprehensive, unbiased and
116 systematic approach to selection and prioritisation of drugs for clinical trials. Structured
117 expert led guidance have been used in in secondary progressive multiple sclerosis,(13)
118 Alzheimer’s disease,(14) and Parkinson’s disease,(15) where expert committees are convened
119 to suggest relevant mechanisms and longlist drugs acting on these mechanisms. Drug
120 “Curriculum Vitae” (CVs) with a standard template including information on
121 pharmacodynamics, pharmacokinetics, mechanism of action, and *in vitro*, *in vivo* and clinical
122 trials evidence base are completed by members of the committee and scored to inform further
123 rounds of shortlisting. However, without systematic evidence synthesis, incomplete capture
124 of information to this process may result in promising candidate drugs being missed and
125 evidence being overstated, while inconsistencies in compilation and presentation of
126 information by contributors from different backgrounds may introduce bias.(13)

127

128 We used clinical and preclinical systematic reviews to guide expert panel discussions for
129 drug selection in the Multiple Sclerosis – Secondary Progressive Multi-Arm Randomisation
130 Trial)(16, 17) and for the first two treatment arms of MND-SMART.(7, 18) This phase III
131 multi-arm multi-stage trial began recruiting in February 2020, with three treatment groups
132 comprising placebo, memantine, and trazodone, and by October 2022 had randomised 400
133 participants. The trial design enables discontinuation of treatment arms that are ineffective
134 and addition of new treatment arms. The trial investigators seek to identify and prioritise a
135 pipeline of suitable, ‘trial ready’ candidate drugs for future addition. The main challenge is in
136 producing an up-to-date summary of the available evidence, given the time taken to complete

137 systematic reviews. Further, an approach based purely on the published literature may
138 overlook other therapeutic approaches, which might be suggested for instance by unbiased
139 drug screening assays or disease-specific pathophysiology (to the extent that this is known).

140

141 Recent innovations in systematic review and evidence synthesis technology, including
142 automation tools, machine-learning (ML) and text-mining techniques, have made it feasible
143 to perform living systematic reviews at scale, and to produce living evidence summaries to
144 inform practice and policy.(19, 20) In parallel, advances in human-induced pluripotent stem
145 cells, gene editing and multi-omics technology have facilitated rapid expansion of our
146 understanding of MND disease and related biology and the identification of putative
147 therapeutic targets and pathways, some of which are shared across neurodegenerative
148 diseases.(21) Automated high throughput phenotypic *in vitro* drug screening technology has
149 enabled comprehensive screening of compound libraries representing approved drugs and
150 potential clinical candidates on human-derived models at scale and at speed.(22) The past
151 decade has also seen rapid development and progress in computational and bioinformatics
152 tools and resources which integrate and leverage multiple data types to generate drug-target-
153 phenotypic hypotheses. Noting these advances across disciplines, we aimed to develop a
154 systematic and structured framework to integrate data from different domains (including
155 expert opinion) to identify, evaluate and prioritise candidate drugs for evaluation in MND-
156 SMART.

157

158 Results

159 Our drug identification, evaluation, and prioritisation process for the next arm of MND-
160 SMART is summarised in Figure 1. In September 2019, 20383 publications were retrieved
161 from our Repurposing Living Systematic Review – Motor Neuron Disease (ReLiSyR-MND)
162 living clinical search, of which 6138 publications describing 798 interventions were included.
163 Of these, 196 interventions described in 1660 clinical publications met the ReLiSyR logic,
164 and of these, 45 drugs described in 1082 clinical publications met the longlisting criteria in
165 place at that time (listed in the British National Formulary, prescription-only medicine
166 available in oral formulation and not previously in the 2017 ‘red list’ during selection of the
167 first two arms of MND-SMART, deemed by investigators to be appropriate for MND-
168 SMART). For these publications we undertook annotation and data extraction from clinical,
169 animal *in vivo* and *in vitro* publications within ReLiSyR-MND.

170

171 In April 2021, the number of clinical publications retrieved in our living search had increased
172 to 20770, of which 6533 publications describing 808 interventions were included. 303
173 interventions described in 4440 publications met the ReLiSyR logic. In parallel, on primary
174 *in vitro* screening, we identified 171 positive astrocyte monochlorobimane (MCB) hits and
175 116 positive hits which reduced wild-type and/or mutant TDP-43 protein aggregates in
176 HEK293 cells and human stem cell-derived motor neurons under oxidative stress (sodium
177 arsenite). We identified 1144 compounds of interest by weighted gene co-expression network
178 analysis (WGCNA) using TargetALS RNA-sequencing data. We performed dose response *in*
179 *vitro* screening in triplicates on astrocyte MCB and motor neuron TDP-43 assays for all drugs
180 longlisted in 2019, all positive hits on primary screen and 37 compounds identified on
181 WGCNA which met ReLiSyR logic. 38 astrocyte MCB hits and 16 TDP-43 hits were


182 confirmed on dose response retest. We added four drugs meeting ReLiSyR logic and showing
183 activity on *in vitro* screening to our longlist and generated further evidence across all domains
184 for longlisted drugs.

185

186 In October 2021, we reviewed the above data, and mechanistic data from DrugBank
187 (www.drugbank.ca) and PubChem with a particular focus on (i) drugs with high ReLiSyR
188 scores in the current review and in 2017, (ii) ‘rapid risers’ – drugs with large improvements
189 in ReLiSyR rankings from 2017 and (iii) drugs featuring in the current review of ReLiSyR
190 which were not included in the 2017 review, and (iv) drugs showing compelling evidence
191 from other sources including published preclinical studies, *in vitro* screening, pathway and
192 network analysis, and preprints. The group shortlisted nine drugs for further evaluation.

193 Following expert panel review of the expanded literature search, scoping of manufacturing
194 feasibility and multiparametric phenotypic screening in triplicate with dose response testing,
195 two drugs, amantadine and ropinirole were upgraded to Group 1 in January 2022, with
196 amantadine selected as the third experimental arm for MND-SMART. ReLiSyR clinical data
197 used for the shortlisting process are shown in Figure 2.

198 *Figure 1 Identification, evaluation and prioritisation of candidate drugs. MCB: monochlorobimane; pubs: publications;*
 199 *WGCNA weighted gene co-expression network analysis.*



200

201

202 Figure 2 Scores from ReLiSyR-MND clinical review used to inform prioritisation of candidate drugs (as of 28 April 2022).

203 (A) Violin plot showing distribution of ReLiSyR drug score for longlisted drugs. Group 1 drugs are shaded in black. (B)


204 Bubble plot showing ReLiSyR clinical review subscores for all longlisted drugs. Drugs recommended for clinical trial are

205 marked with crosses. Other shortlisted drugs are marked with arrows. (C) Changes in drug scores for drugs between

206 previous review concluded in 2017 and the current review. Shortlisted drugs are labelled. Scores shown are rescaled by

207 min-max normalisation, where $score_{scaled} = \frac{score - score_{min}}{score_{max} - score_{min}}$.

208



209

210 **Amantadine**

211 Amantadine is a synthetic tricyclic amine with antiviral, antiparkinsonian and
212 antihyperalgesic activities. Amantadine is licensed in the UK for treatment of Parkinson's
213 disease and post-herpetic neuralgia, and treatment and prophylaxis of influenza A.
214 Amantadine is also used for fatigue in multiple sclerosis but is not licensed for this indication.
215 Amantadine is a weak dopamine agonist (which may give rise to its antiparkinsonian effects)
216 and interferes with a viral protein, M2. Amantadine also targets NMDA glutamate receptors,
217 and this may be relevant to glutamate-induced neurotoxicity in neurodegenerative diseases.
218

219 We identified 59 publications describing the use of amantadine in a total of 2201 participants
220 (Table 1), along with 2 preprints in multiple sclerosis (171 participants) as of 28 April 2022.
221 Amantadine ranked 7 out of 47 longlisted drugs. Efficacy (median 2.53, range: -2 - 4) and
222 safety (median 2; range: 0-3) subscores were favourable. Amantadine has previously been
223 trialled in ALS in 1981 in a small, double-blind crossover randomised controlled trial of
224 amantadine (100 mg three times daily), guanidine and placebo over 6-month treatment
225 periods.(34) While the study did not show significant improvement in a measure based on
226 functional performance and strength, no quantitative data were presented. Amantadine was
227 tolerated well.

228 *Table 1 Characteristics and number of patients / participants of clinical studies for amantadine identified via ReLiSyR-*
229 *MND.*

Disease	Study Type	Number of Studies	Number of Participants
Huntington's disease	Interventional	3	57
Motor neuron disease	Interventional	1	10
Multiple sclerosis	Interventional	11	452
Parkinson's disease	Interventional	34	1240


	Observational	10	442
Total		59	2201

230

231 Intracellular TDP-43 aggregates are seen in 97% of MND post mortem cases and in 40% of
232 frontotemporal dementia (FTD) post mortems, and it is likely to contribute to neuronal
233 death.(35) Thus, drugs able to reverse the pathological accumulation of TDP-43 aggregates
234 are strong candidates for testing in clinical trials. On *in vitro* screening, amantadine was
235 effective in clearing TDP-43 cytoplasmic aggregates *in vitro* in human neurons derived from
236 people with MND, significantly reducing the number and size of TDP-43+ aggregates
237 (Figure 3).

238

239 *Figure 3 Dose-response curve for treatment of human stem cell-derived spinal motor neurons with amantadine depicting*
240 *reduction in number (A) and area (B) of TDP-43+ aggregates. * $p < 0.05$, two-sample Student's t-test to vehicle control*
241 *(0uM).*



242

243

244 In parallel, using target prediction by SEA and STRING network analysis, we built a
245 predicted protein-protein interaction network for amantadine (Figure 4). There was a strong

246 overlap between proteins within this network and association with MND based on disease


247 association scores from the Open Targets Platform.

248

249 *Figure 4 Protein-protein interaction network for amantadine based on target prediction using Similarity Ensemble*

250 *Approach and expansion by STRING database to the nearest 20 proteins. Shade of nodes represent MND disease*

251 *association scores for targets obtained from Open Targets Platform, with darker shades representing stronger association.*



252

253 Amantadine is well absorbed orally, has good predicted BBB penetrance and can be given as

254 a once daily oral solution, matching the other investigational medicinal products currently

255 tested within MND-SMART.

256

257 Discussion

258 Translational success has remained elusive across neurodegenerative diseases. However, the

259 accelerating pace of research and advances across biological domains: ‘-omics’ fields from

260 genomics, metabolomics, proteomics, transcriptomics to epidemiology with wider and more

261 in-depth phenotypic capture of population data via disease registries, and wearable

262 technologies provide an ever-expanding wealth of data which can be instrumental in

263 achieving improved clinical outcomes. These data may indeed hold key insights towards
264 improving our understanding of underlying disease mechanisms and developing effective
265 treatments to slow, stop and reverse these processes. The emergence of adaptive platform
266 trials in neurodegenerative diseases brings a new challenge – to identify, evaluate, and select
267 the best available candidate drugs for evaluation in clinical trials within the timeframe of trial
268 adaptation epochs. To unlock the potential of large and rapidly expanding amounts of data
269 which are often siloed to inform such decisions, developing methods to provide a continually
270 up-to-date, systematic, broad-scope synthesis and mapping of emerging evidence across
271 relevant domains is crucial.

272

273 As a starting point, we built upon our previous clinical and preclinical systematic reviews
274 informing the selection of the first two arms of MND-SMART. To make it feasible for
275 ReLiSyR to provide up-to-date synthesis of the rapidly expanding literature, our updated
276 methodology incorporates living updates of systematic searches and automated removal of
277 duplicate records, machine learning-assisted citation screening for inclusion, automated
278 annotation of drug and disease mechanisms studied in each publication. Further updates to
279 the Systematic Review Facility (SyRF) platform(19, 24, 36) enables efficient project
280 management, data management, implementation of systematic review tools and
281 crowdsourcing of annotations, efficient workflows via R and R Shiny to automate scoring,
282 analysis, reporting including visualisation and updates to MND-SOLES-CT.(19, 25, 37)

283

284 Our approach to drug selection has evolved with accumulating experience and expansion of
285 our networks to incorporate more domains and gather more in-depth data with adaptations to
286 better suit current clinical trial protocol and requirements. We adopted a modular approach to
287 enable flexibility to incorporate other suitable data domains. High-throughput *in vitro*

288 screening of comprehensive drug libraries allows evaluation of drug-target hypotheses in the
289 context of all existing drug-target classes to facilitate benchmarking and prioritization.

290 Further integration with pathway and network analysis provide means of evaluating disease-
291 specific pathophysiology for candidate drugs identified via ReLiSyR. The addition of other
292 domains has had a synergistic effect on our evidence synthesis, with each domain informing
293 further development of other domains – for example, where we have used ReLiSyR data to
294 select drugs for more in-depth *in vitro* screening and vice-versa.

295

296 As our primary aim is to inform drug selection within trial adaptation cycles for a phase III
297 multi-arm multi-stage trial, drug repurposing – using an established drug in a novel indication
298 – offers significant advantages over evaluation of novel compounds with shorter development
299 timelines, availability of safety data and lower costs, and is thus our current focus. Novel
300 compounds of interest identified can be evaluated further in preclinical studies and early
301 phase clinical trials to gather further data for future consideration in MND-SMART.

302

303 **Limitations**

304 One of our challenges is to evaluate, synthesise and summarise large amounts of data from
305 different domains in an intuitive, informative, and understandable manner for our expert
306 panel. Currently, for longlisted drugs, we do this for each domain separately and present
307 these in our drug CVs and via our app. With increasing numbers of drugs to consider, a
308 scoring system which produces one overall score reflecting the suitability of each drug for
309 evaluation in clinical trials using evidence across all domains could prove useful. To achieve
310 this, we need to develop methods to evaluate the strength and relevance of each domain in
311 comparison to the others and weigh them accordingly. However, this is challenging in a

312 disease where few effective disease-modifying treatments exist and the ‘absolute truth’ of
313 how informative each of these domains are in predicting the likelihood of translational
314 success remains unknown.

315

316 The other challenge is to produce accurate ‘real-time’ evidence summaries. The innovations
317 in ReLiSyR have enabled us to produce a 'real-time' living evidence summary of publications
318 retrieved from biomedical databases, deduplicated, screened for inclusion and annotated with
319 drug and disease studied to inform the longlisting of candidate drugs. However, more in-
320 depth annotation of publications for longlisted drugs is currently a time-consuming process
321 fully dependent on human reviewers. We have thus limited the number of longlisted drugs for
322 in-depth annotations within ReLiSyR to ensure these are completed within trial adaptation
323 timelines, noting a lead time required for trial protocol amendments, discussions with
324 regulators and sponsors, and manufacturing prior to inclusion of the selected drug in MND-
325 SMART.

326

327 The current MND-SMART master protocol employs the same eligibility criteria, dosing
328 regimen and route across all treatment arms, with all investigational medicinal products
329 manufactured as matched oral solutions, thus limiting the scope of drugs which can be
330 feasibly evaluated within the trial. Planning of a protocol amendment to allow different
331 eligibility criteria, dosing regimens and routes for different treatment arms is ongoing.

332

333 **Future directions**

334 Other suitable domains, such as epidemiology, clinical trial data, and other multiomics data
335 can be added to our modular framework to increase the breadth of evidence synthesised.

336 Ongoing progress in other systematic review, evidence synthesis and automation tools
337 including those in other Systematic Online Living Evidence Summary projects are potentially
338 transferrable to our workflow.(19, 20) The expanding datasets from human annotations and
339 data extraction in ReLiSyR can be used to train and validate further machine learning models
340 to further improve efficiency. Developing evidence synthesis at the levels of pathways and
341 targets in addition to current synthesis at the level of drugs may be helpful to inform
342 prioritisation of targets and pathways for further research and drug development, and for
343 consideration of combination treatments. The overall framework could be adapted and
344 implemented in other diseases, especially in adaptive platform trials.


345

346 **Conclusion**

347 We demonstrate the feasibility of using a modular framework with data from different
348 domains to inform systematic prioritisation and evaluation of candidate drugs for an adaptive
349 platform trial in MND, with potential applications in other diseases. Work to expand the
350 breadth, depth and efficiency of evidence synthesis within the framework is ongoing.

351 Material and methods

352 *Figure 5 The Systematic Living Evidence for Clinical Trial (SyLECT) framework.*



353

354 The principle underpinning our work is that prioritisation of candidate drugs for an ongoing
355 adaptive platform trial is best informed by the systematic gathering, evaluation and synthesis
356 of all evidence available at that time. To best inform drug selection at the pace required for
357 trial adaptations, this process must be able to rapidly and efficiently identify then prioritise
358 candidate drugs, followed by more in-depth evidence generation, evaluation and synthesis for
359 prioritised drugs. This expansion in scope, breadth and depth of the evidence synthesised,
360 adaptation to best suit clinical trial requirements, and improvement in efficiency of evidence
361 synthesis over time also needs to proceed at pace. Against this background, we developed the
362 SyLECT (Systematic Living Evidence for Clinical Trials) Framework (Figure 5).

363 Importantly, the automation tools and algorithms used to synthesise information from
364 different domains are subject to continual improvement; the current implementation of
365 SyLECT is described below.

366 We identify suitable and available domains of data to provide evidence on efficacy, safety,
367 feasibility, and pharmacological and biological profiles of candidate drugs. For the current
368 iteration we are again seeking an existing drug suitable for repurposing. We began with
369 summarising published data for drugs tested in neurodegenerative diseases (curated in the
370 ReLiSyR-MND platform (23); stable version: <https://camarades.shinyapps.io/reლისyr-v1/>) and
371 recommendations from experts. We have since added consideration of domains describing
372 findings from *in vitro* high throughput phenotypic drug screening, pathway and network
373 analysis, and mining of drug, compound, and clinical trial databases. We generate an
374 integrated candidate drug list using these domains and filter drugs with our prioritisation
375 criteria via the ICAN-MND (Integrated Candidate Drug List for MND) app, an interactive
376 web application (demo version: <https://camarades.shinyapps.io/ican-mnd-demo>). Our expert
377 panel create a longlist of drugs from the filtered list. For longlisted drugs, we generate,
378 evaluate, and synthesise further evidence across domains. We report living evidence
379 summaries using MND-SOLES-CT (Motor Neuron Disease – Systematic Online Living
380 Evidence Summary for Clinical Trials; demo version: [https://camarades.shinyapps.io/mnd-
381 soles-ct-demo](https://camarades.shinyapps.io/mnd-soles-ct-demo)), an interactive web application which can be explored by the expert panel to
382 inform their decisions on drug shortlisting and selection at trial adaptation boundaries.

383

384 **Identifying candidate drugs**

385 (i) Repurposing Living Systematic Review – Motor Neuron Disease (ReLiSyR-
386 MND)

387 ReLiSyR-MND is a ML-assisted, three-part living systematic review of clinical studies of
388 MND and other neurodegenerative diseases (Alzheimer dementia, FTD, Huntington disease,
389 Parkinson disease and multiple sclerosis) which may share similar pathways; animal *in vivo*

390 studies of MND and FTD models (the latter included because of the pathological overlap
391 between FTD and MND); and *in vitro* literature describing human induced pluripotent stem
392 cell based MND and FTD models. ReLiSyR builds upon our clinical and preclinical
393 systematic reviews which concluded in 2017 informing the first two arms of MND-SMART.
394 (7, 18) The protocol of ReLiSyR-MND has been updated with accumulating experience since
395 its conception. The complete record of the protocol, including changes made, is available on
396 Open Science Framework.(23) Using Systematic Review Facility (SyRF; syrf.org.uk;
397 RRID:SCR_018907),(24) a web application for systematic reviews, we conduct a living
398 search with weekly automated retrieval of citations from Pubmed via an Application
399 Programming Interface (API). Using a ML-algorithm trained on more than 5000 dual-
400 screened human decisions (sensitivity 95%, specificity 81%, precision 67%), citations are
401 screened for inclusion based on title and abstract. We use text mining (Regular Expressions
402 deployed in R(25)) to annotate included publications for drug and disease studied. We then
403 select drugs described in at least one clinical publication in MND OR in clinical publications
404 in two other diseases of interest (the “ReLiSyR logic”).

405

406 (ii) *In vitro* high throughput drug screening

407 We performed multi-parametric high throughput screening of the Prestwick Chemical
408 Library, the TargetMol drug repurposing library, and the TargetMol Natural Product Library
409 (6651 compounds) spanning all major drug-target classes, including United States Food and
410 Drugs Administration-approved drugs using validated in-house phenotypic assays. Current
411 assays include human astrocyte antioxidant assays and a TDP43 protein aggregation assay.
412 Drug screening methods are detailed in a separate publication (in progress).

413

414 Primary screening for these assays were performed in 384-well format to industry standards
415 of reproducibility and signal-to-noise using liquid handling robotics and automated image
416 acquisition and analysis (ImageXpress-confocal platform), with libraries professionally
417 stored, curated and plated by BioAscent.

418

419 (iii) Pathway and network analysis

420 We perform weighted gene co-expression network analysis (WGCNA) on RNA-sequencing
421 (RNA-seq) data from the TargetALS consortium of postmortem brains of people with MND
422 and controls.(26) From this we identify network modules significantly associated with MND
423 (because these may signify possible underlying dysfunction or secondary pathophysiological
424 effects) and use this to identify compounds which target proteins within these networks.

425 Where these targets are not amenable to drug treatment in humans due to toxicity, feasibility,
426 or pharmacological issues such as poor BBB penetrance of existing drugs, we conduct further
427 analysis to identify potential upstream or downstream targets and candidate drugs which may
428 act on those targets.

429

430 (iv) Mining drug, compound and trial databases

431 We mine ChEMBL,(27, 28) admetSAR2.0,(29) and ClinicalTrials.gov to obtain data on
432 pharmacology, chemical and physical properties, mechanisms of action, predictions on BBB
433 penetrance, and MND clinical trials.

434

435 (v) Expert panel

436 We gather recommendations from our panel consisting of MND triallists, clinicians,
437 scientists, and experts in drug screening, pharmacology, and systematic reviews.

438

439 Reporting candidate drugs identified

440 We report all candidate drugs identified across the domains using ICAN-MND. In this app,

441 users can select categories of evidence of interest (protein aggregation screening hits,

442 astrocyte oxidation assay hits, drugs in any ReLiSyR included publications, drugs meeting

443 ReLiSyR drug/disease logic, current longlisted drugs and/or WGCNA predictions) and filters

444 (admetSAR2.0(29) prediction of BBB permeability, oral formulation, prescription only

445 medicine, listed in the British National Formulary). The app generates an Euler plot

446 visualising number of drugs in each set, and where these sets overlap, and tabulate drugs

447 meeting the criteria selected.

448

449 **Evaluating and prioritising candidate drugs**

450 Using our framework, we inform expert panel decisions in prioritising candidate drugs into

451 three groups: Group 1: suitable for evaluation in clinical trial; Group 2: for further evidence

452 generation, synthesis, and reporting; and Group 3: not for further consideration (Box 1).

Box 1: Priority groups for candidate drugs

Group 1: Recommended for clinical trial

Group 2: Recommended for further evidence generation, synthesis, and reporting.

- Group 2A: Drugs suitable for imminent evaluation in MND-SMART, pending further evidence synthesis and evaluation.
- Group 2B: Drugs not suitable for imminent evaluation in MND-SMART but may yield important data for pathway and network analysis or be suitable for other clinical trials including early phase trials.
- Group 2C: Drugs not suitable for imminent evaluation in MND-SMART, due to pharmacological and feasibility profiles. Candidates for further mechanistic and drug development studies.

Group 3: Not recommended for further evaluation.

453 We identify candidate drugs meeting ReLiSyR logic, or those with positive hits on primary
454 screening in relevant *in vitro* screening assays, or promising WGCNA predictions from
455 TargetALS RNA-Seq data,(26) or suggestions from the expert panel. From these, we take
456 forward candidates meeting all the following criteria: listed in the British National
457 Formulary,(30) status as prescription only medicine (to prevent self-administration of over-
458 the-counter trial drugs which may compromise trial integrity), availability in oral
459 formulation, and predicted BBB permeability. We remove candidates which have been
460 previously deemed unsuitable for clinical trials by the expert panel (due to prior definitive
461 testing in MND clinical trials, lack of biological plausibility or poor safety profile) unless
462 there is overwhelming new evidence to justify reconsideration. The expert panel reviews
463 reported safety, biological plausibility, feasibility, and suitability of remaining candidate
464 drugs to create a longlist for further evaluation (Group 2A). The expert panel may assign
465 candidate drugs which do not meet the criteria above to lower priority groups (Group 2B or
466 2C) for further evaluation.

467

468 For longlisted drugs, we curate further evidence across the different domains:

469 (i) ReLiSyR-MND: We recruit and train a crowd of reviewers to annotate and extract
470 outcome data from publications for longlisted drugs, using the SyRF platform.(24)
471 Each publication is annotated independently by two reviewers, with discrepancies
472 reconciled by a third reviewer. For the clinical review, using a predefined metric,
473 we programmatically score each drug in each publication on a combination of
474 efficacy and safety and weighted by study quality scored using a modified
475 GRADE (Grading of Recommendations, Assessment, Development and
476 Evaluations) framework and study size.(23) We combine data for each drug across
477 publications taking the median publication score for each drug and number of

478 contributing publications, and rank them accordingly. For *in vivo* and *in vitro*
479 studies, we generate forest plots summarising the treatment effect of each
480 longlisted intervention. Where there are three or more publications reporting the
481 effect of an intervention in at least five independent experiments we conduct a
482 formal meta-analysis.

483 (ii) Experimental drug screening: To validate positive hits from primary *in vitro*
484 screens we perform 8-point semi-log dose response confirmation experiments,
485 using alternative suppliers. We performed secondary screening protocols using
486 protein aggregation assays and neurotox assays. Details of these are within a
487 separate publication by the drug screening team.

488 (iii) Pathway and network analysis: We perform protein-target prediction for each
489 longlisted drug using the structural similarity ligand-based target prediction
490 approach, SEA (Similarity Ensemble Approach)(31), using Z score >1.96 and
491 MaxTc (Tanimoto coefficient) greater than 0.4 as thresholds) with compound
492 SMILES (simplified molecular-input line-entry system) as input. We then build
493 protein-protein interaction networks using STRING database by expanding from
494 predicted targets to the nearest 20 proteins.(32) We then perform pathway
495 enrichment analysis to identify biological pathways hit by each compound.
496 Separately, we search the Open Targets Platform for targets associated with
497 “amyotrophic lateral sclerosis” and their disease association scores based on
498 genetic associations, somatic associations, drugs, pathways and system biology,
499 RNA expression and animal models. We map predicted protein-protein interaction
500 network for each drug to these disease association scores.

501 (iv) Drug databases: We mine data from the ChEMBL(27, 28) database to gather
502 pharmacological information such as pharmacokinetics and pharmacodynamics

503 data, chemical and physical properties, and mechanism of action. We gather data
504 on prescribing, safety, licensing, and medicinal forms from the British National
505 Formulary.(30)

506

507 We provide a curated living evidence summary from all the domains using an interactive
508 application, MND-SOLES-CT and use R Markdown (33) to automate generation of
509 timestamped parameterised drug CVs for drug selection to inform expert panel discussions.
510 The expert panel meets at trial adaptation boundaries to discuss candidates for shortlisting.
511 For shortlisted drugs, we expand our literature search to include preprint servers, and extract
512 further data on safety, tolerability, and dosing. We evaluate suitability of shortlisted drugs
513 based on current trial protocol and consider impact on trial eligibility criteria, dosing schedule
514 and feasibility in manufacturing compounds in forms matching other current investigational
515 medicinal products within MND-SMART. Candidate drugs recommended for clinical trials
516 are re-assigned from Group 2A to Group 1.

517

518 **ACKNOWLEDGMENTS**

519 We would like to thank the evidence synthesis and data science communities, including the
520 Collaborative Approach to Meta Analysis and Review of Animal Experimental Studies
521 (CAMARADES) group and developers of R, R Shiny, R Markdown, Tidyverse and SyRF for
522 continued improvement and updates of tools and packages to facilitate the development of
523 SyLECT. We would also like to thank providers of data and resources used in SyLECT,
524 including The Target ALS Human Postmortem Tissue Core, New York Genome Center for
525 Genomics of Neurodegenerative Disease, the Amyotrophic Lateral Sclerosis Association and
526 the Tow Foundation, EMBL-European Bioinformatics Institute.

527

528 ReLiSyR-MND consortium members: Charis Wong, Jenna M. Gregory, Jing Liao, Kieren
529 Egan, Hanna M. Vesterinen, Aimal Ahmad Khan, Maarij Anwar, Caitlin Beagan, Fraser
530 Brown, John Cafferkey, Alessandra Cardinali, Jane Yi Chiam, Claire Chiang, Victoria
531 Collins, Joyce Dormido, Elizabeth Elliott, Peter Foley, Yu Cheng Foo, Lily Fulton-Humble,
532 Angus B. Gane, Stella A. Glasmacher, Áine Heffernan, Kiran Jayaprakash, Nimesh
533 Jayasuriya, Amina Kaddouri, Jamie Kiernan, Huw Knapper, Gavin Langlands, Danielle
534 Leighton, Jiaming Liu, James Lyon, Olena Makysm, Arpan R. Mehta, Alyssa Meng,
535 Vivienne Nguyen, Na Hyun Park, Suzanne Quigley, Yousuf Rashid, Andrea Salzinger,
536 Bethany Shiell, Ankur Singh, Tim Soane, Alexandra Thompson, Olaf Tomala, Fergal M.
537 Waldron, Bhuvaneish T. Selvaraj, Jeremy Chataway, Robert Swingler, Peter Connick,
538 Suvankar Pal, Siddharthan Chandran, Malcolm R. Macleod

539

540 **CONTRIBUTIONS**

- 541 Project conceptualisation: CW, AC, SP, SC, MM
- 542 Data curation: CW, AC, JLiao, BTS, PB, RC, JLongden
- 543 Formal analysis: CW, AC, JLiao, BTS, PB, RC, JLongden, RG, MM
- 544 Funding acquisition: SC
- 545 Investigation: CW, AC, JLiao, BTS, PB, RC, JLongden, MM, ReLiSyR-MND consortium
- 546 Methodology: CW, AC, PB, RC, SP, GH, NC, SC, MM
- 547 Project administration: CW, AC, JLiao, BTS
- 548 Software: CW, JLiao, AC
- 549 Supervision: SP, GH, NC, SC, MM
- 550 Validation: CW, AC, BTS, PB, RC
- 551 Visualisation: CW, AC, BTS, RG
- 552 Drug selection group: CW, AC, BTS, RC, PB, RD, JC, RS, SP, SC, MM
- 553 Writing – original draft: CW, AC, BTS
- 554 Writing – review and editing: CW, AC, JLiao, BTS, PB, RC, JLongden, RH, RD, SP, JC, RS,
555 GH, NC, SC, MM

556 **FUNDING**

- 557 MND-SMART is funded by grants from MND Scotland, My Name's Doddie Foundation
558 (DOD/14/15) and specific donations to the Euan MacDonald Centre. SC receives funding
559 from UK Research and Innovation (Medical Research Council) (DRI-CORE-2017-EDI). The
560 study funders have no role in study design, data collection, data analysis, data interpretation
561 or writing of publications. For the purpose of open access, the author has applied a Creative

562 Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising
563 from this submission.

564

565 **COMPETING INTERESTS**

566 In the last 3 years, J. Chataway has received support from the Efficacy and Evaluation (EME)
567 Programme, a Medical Research Council (MRC) and National Institute for Health Research
568 (NIHR) partnership and the Health Technology Assessment (HTA) Programme (NIHR), the
569 UK MS Society, the US National MS Society and the Rosetrees Trust. He is supported in part
570 by the NIHR University College London Hospitals (UCLH) Biomedical Research Centre,
571 London, UK. He has been a local principal investigator for a trial in MS funded by the
572 Canadian MS society. A local principal investigator for commercial trials funded by:
573 Actelion, Novartis and Roche; and has taken part in advisory boards/consultancy for
574 Azadyne, Janssen, Merck, NervGen, Novartis and Roche.

575

576

577

578

579 REFERENCES


- 580 1. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis
581 (ALS)/motor neuron disease (MND). *Cochrane Database Syst Rev.* 2012;2012(3):Cd001447.
- 582 2. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral
583 sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol.*
584 2017;16(7):505-12.
- 585 3. Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of
586 Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. *New England*
587 *Journal of Medicine.* 2020;383(10):919-30.
- 588 4. Paganoni S, Hendrix S, Dickson SP, Knowlton N, Macklin EA, Berry JD, et al. Long-
589 term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in
590 amyotrophic lateral sclerosis. *Muscle Nerve.* 2021;63(1):31-9.
- 591 5. Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernández M, et al. Masitinib as an
592 add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized
593 clinical trial. *Amyotroph Lateral Scler Frontotemporal Degener.* 2020;21(1-2):5-14.
- 594 6. Wong C, Stavrou M, Elliott E, Gregory JM, Leigh N, Pinto AA, et al. Clinical trials in
595 amyotrophic lateral sclerosis: a systematic review and perspective. *Brain Commun.*
596 2021;3(4):fcab242.
- 597 7. Wong C, Dakin RS, Williamson J, Newton J, Steven M, Colville S, et al. Motor
598 Neuron Disease Systematic Multi-Arm Adaptive Randomised Trial (MND-SMART): a
599 multi-arm, multi-stage, adaptive, platform, phase III randomised, double-blind, placebo-
600 controlled trial of repurposed drugs in motor neuron disease. *BMJ Open.*
601 2022;12(7):e064173.




- 602 8. Paganoni S, Berry JD, Quintana M, Macklin E, Saville BR, Detry MA, et al. Adaptive
603 Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. *Ann*
604 *Neurol.* 2022;91(2):165-75.
- 605 9. van Eijk RPA, Kliet T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al.
606 TRICALS: creating a highway toward a cure. *Amyotroph Lateral Scler Frontotemporal*
607 *Degener.* 2020;21(7-8):496-501.
- 608 10. Mehta AR, Pal S, Chataway J, Carpenter JR, Parmar MKB, Chandran S. Smarter
609 adaptive platform clinical trials in neurology: a showcase for UK innovation. *Brain.* 2022.
- 610 11. Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, et al.
611 Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic
612 lateral sclerosis with SOD1 mutations. *Ann Neurol.* 2007;61(5):427-34.
- 613 12. Perrin S. Preclinical research: Make mouse studies work. *Nature.*
614 2014;507(7493):423-5.
- 615 13. Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, et al. Systematic
616 approach to selecting licensed drugs for repurposing in the treatment of progressive multiple
617 sclerosis. *J Neurol Neurosurg Psychiatry.* 2021;92(3):295-302.
- 618 14. Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, et al. Drug
619 repositioning for Alzheimer's disease. *Nat Rev Drug Discov.* 2012;11(11):833-46.
- 620 15. Brundin P, Barker RA, Conn PJ, Dawson TM, Kieburz K, Lees AJ, et al. Linked
621 clinical trials--the development of new clinical learning studies in Parkinson's disease using
622 screening of multiple prospective new treatments. *J Parkinsons Dis.* 2013;3(3):231-9.
- 623 16. Vesterinen HM, Connick P, Irvine CM, Sena ES, Egan KJ, Carmichael GG, et al.
624 Drug repurposing: a systematic approach to evaluate candidate oral neuroprotective
625 interventions for secondary progressive multiple sclerosis. *PLoS One.* 2015;10(4):e0117705.



- 626 17. Chataway J, De Angelis F, Connick P, Parker RA, Plantone D, Doshi A, et al.
627 Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-
628 SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. *Lancet*
629 *Neurol.* 2020;19(3):214-25.
- 630 18. Wong C, Gregory JM, Liao J, Egan K, Vesterinen HM, Khan AA, et al. A Systematic
631 Approach to Identify Neuroprotective Interventions for Motor Neuron Disease. *medRxiv.*
632 2022:2022.04.13.22273823.
- 633 19. Bannach-Brown A, Hair K, Bahor Z, Soliman N, Macleod M, Liao J. Technological
634 advances in preclinical meta-research. *BMJ Open Sci.* 2021;5(1):e100131.
- 635 20. Hair K, Wilson E, Wong C, Tsang A, Macleod MR, Bannach-Brown A. Systematic
636 Online Living Evidence Summaries: Emerging Tools to Accelerate Evidence Synthesis.
637 *MetaArXiv.* 2022.
- 638 21. Morello G, Salomone S, D'Agata V, Conforti FL, Cavallaro S. From Multi-Omics
639 Approaches to Precision Medicine in Amyotrophic Lateral Sclerosis. *Front Neurosci.*
640 2020;14:577755.
- 641 22. McGown A, Stopford MJ. High-throughput drug screens for amyotrophic lateral
642 sclerosis drug discovery. *Expert Opin Drug Discov.* 2018;13(11):1015-25.
- 643 23. Wong CL, J.; Gregory, J.; Pal, S.; Chandran, S.; Macleod, M. Study protocol:
644 ReLiSyR-MND (Repurposing Living Systematic Review –Motor Neuron Disease): A
645 systematic approach to identify neuroprotective interventions for motor neuron disease.
646 Version 2. 2022 [updated 23 June 2022. Available from: <https://osf.io/bkscj>.
- 647 24. Bahor Z, Liao J, Currie G, Ayder C, Macleod M, McCann SK, et al. Development and
648 uptake of an online systematic review platform: the early years of the CAMARADES
649 Systematic Review Facility (SyRF). *BMJ Open Sci.* 2021;5(1):e100103.

- 650 25. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
651 Austria 2022.
- 652 26. Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem
653 Cortex Samples Identify Distinct Molecular Subtypes of ALS: Retrotransposon Activation,
654 Oxidative Stress, and Activated Glia. *Cell Rep.* 2019;29(5):1164-77.e5.
- 655 27. Mendez D, Gaulton A, Bento AP, Chambers J, De Veij M, Félix E, et al. ChEMBL:
656 towards direct deposition of bioassay data. *Nucleic Acids Res.* 2019;47(D1):D930-d40.
- 657 28. Davies M, Nowotka M, Papadatos G, Dedman N, Gaulton A, Atkinson F, et al.
658 ChEMBL web services: streamlining access to drug discovery data and utilities. *Nucleic*
659 *Acids Res.* 2015;43(W1):W612-20.
- 660 29. Yang H, Lou C, Sun L, Li J, Cai Y, Wang Z, et al. admetSAR 2.0: web-service for
661 prediction and optimization of chemical ADMET properties. *Bioinformatics.*
662 2019;35(6):1067-9.
- 663 30. British National Formulary (online) [Internet]. BMJ Group and Pharmaceutical Press.
664 2022 [cited 15 August 2022.]. Available from: <http://www.medicinescomplete.com>.
- 665 31. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. Relating
666 protein pharmacology by ligand chemistry. *Nat Biotechnol.* 2007;25(2):197-206.
- 667 32. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, Muller J, et al. STRING 8--a
668 global view on proteins and their functional interactions in 630 organisms. *Nucleic Acids*
669 *Res.* 2009;37(Database issue):D412-6.
- 670 33. Allaire J, Xie Y, McPherson J, Lurashi J, Ushey K, Atkins A, et al. rmarkdown:
671 Dynamic Documents for R. . 2022.
- 672 34. Munsat TL, Easterday CS, Levy S, Wolff SM, Hiatt R. Amantadine and guanidine are
673 ineffective in ALS. *Neurology.* 1981;31(8):1054-5.

- 674 35. Hergesheimer RC, Chami AA, de Assis DR, Vourc'h P, Andres CR, Corcia P, et al.
675 The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in
676 sight? *Brain*. 2019;142(5):1176-94.
- 677 36. Hair K, Bahor Z, Macleod M, Liao J, Sena ES. The Automated Systematic Search
678 Deduplicator (ASySD): a rapid, open-source, interoperable tool to remove duplicate citations
679 in biomedical systematic reviews. *bioRxiv*. 2021:2021.05.04.442412.
- 680 37. Chang W, Cheng J, Allaire J, Sievert C, Schloerke B, Xie Y, et al. shiny: Web
681 Application Framework for R. R package version 1.7.2 ed2022.
- 682





A**B**

SyLECT: Systematic Living Evidence for Clinical Trials

